Abstract: Non-small cell lung cancer （NSCLC） accounts for about 80％-85％ of lung cancer. The main treatment of advanced NSCLC is medical treatment such as chemotherapy which shows poor efficacy. Recently， epidermal growth factor receptor-tyrosine kinase inhibitor （EGFR-TKI） in the treatment of patients with advanced NSCLC has made a new breakthrough. Icotinib as a domestic EGFR-TKI， preclinical studies and clinical studies show that it has promising safety， tolerability and efficacy in patients with advanced NSCLC.